These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
36 related articles for article (PubMed ID: 8814683)
1. Suppression of breast cancer cells resistant to a pure anti-estrogen with CAR-transduced natural killer cells. Lin YZ; Lee CC; Cho DY; Wang YL; Chen CY; Weng CY; Chiu SC; Hung MC; Wang SC Am J Cancer Res; 2021; 11(9):4455-4469. PubMed ID: 34659898 [TBL] [Abstract][Full Text] [Related]
2. Clinical utility of fulvestrant in the treatment of breast cancer: a report on the emerging clinical evidence. Rocca A; Maltoni R; Bravaccini S; Donati C; Andreis D Cancer Manag Res; 2018; 10():3083-3099. PubMed ID: 30214302 [TBL] [Abstract][Full Text] [Related]
4. APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer. Periyasamy M; Patel H; Lai CF; Nguyen VTM; Nevedomskaya E; Harrod A; Russell R; Remenyi J; Ochocka AM; Thomas RS; Fuller-Pace F; Győrffy B; Caldas C; Navaratnam N; Carroll JS; Zwart W; Coombes RC; Magnani L; Buluwela L; Ali S Cell Rep; 2015 Oct; 13(1):108-121. PubMed ID: 26411678 [TBL] [Abstract][Full Text] [Related]
5. Biological effects of fulvestrant on estrogen receptor positive human breast cancer: short, medium and long-term effects based on sequential biopsies. Agrawal A; Robertson JF; Cheung KL; Gutteridge E; Ellis IO; Nicholson RI; Gee JM Int J Cancer; 2016 Jan; 138(1):146-59. PubMed ID: 26178788 [TBL] [Abstract][Full Text] [Related]
6. Fulvestrant regulates epidermal growth factor (EGF) family ligands to activate EGF receptor (EGFR) signaling in breast cancer cells. Zhang X; Diaz MR; Yee D Breast Cancer Res Treat; 2013 Jun; 139(2):351-60. PubMed ID: 23686416 [TBL] [Abstract][Full Text] [Related]
7. Sulfation of fulvestrant by human liver cytosols and recombinant SULT1A1 and SULT1E1. Edavana VK; Yu X; Dhakal IB; Williams S; Ning B; Cook IT; Caldwell D; Falany CN; Kadlubar S Pharmgenomics Pers Med; 2011 Nov; 4():137-145. PubMed ID: 22822301 [TBL] [Abstract][Full Text] [Related]
8. ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1. Dunbier AK; Anderson H; Ghazoui Z; Lopez-Knowles E; Pancholi S; Ribas R; Drury S; Sidhu K; Leary A; Martin LA; Dowsett M PLoS Genet; 2011 Apr; 7(4):e1001382. PubMed ID: 21552322 [TBL] [Abstract][Full Text] [Related]
9. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Ross-Innes CS; Stark R; Holmes KA; Schmidt D; Spyrou C; Russell R; Massie CE; Vowler SL; Eldridge M; Carroll JS Genes Dev; 2010 Jan; 24(2):171-82. PubMed ID: 20080953 [TBL] [Abstract][Full Text] [Related]
10. 17Beta-estradiol suppresses TLR3-induced cytokine and chemokine production in endometrial epithelial cells. Lesmeister MJ; Jorgenson RL; Young SL; Misfeldt ML Reprod Biol Endocrinol; 2005 Dec; 3():74. PubMed ID: 16384532 [TBL] [Abstract][Full Text] [Related]
11. Effects of ICI 182780 on estrogen receptor expression, fluid absorption and sperm motility in the epididymis of the bonnet monkey. Shayu D; ChennaKesava CS; Soundarajan R; Rao AJ Reprod Biol Endocrinol; 2005 Mar; 3():10. PubMed ID: 15743524 [TBL] [Abstract][Full Text] [Related]
12. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Osborne CK; Wakeling A; Nicholson RI Br J Cancer; 2004 Mar; 90 Suppl 1(Suppl 1):S2-6. PubMed ID: 15094757 [TBL] [Abstract][Full Text] [Related]
13. Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. DeFriend DJ; Anderson E; Bell J; Wilks DP; West CM; Mansel RE; Howell A Br J Cancer; 1994 Aug; 70(2):204-11. PubMed ID: 8054267 [TBL] [Abstract][Full Text] [Related]
14. Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Robertson JF; Nicholson RI; Bundred NJ; Anderson E; Rayter Z; Dowsett M; Fox JN; Gee JM; Webster A; Wakeling AE; Morris C; Dixon M Cancer Res; 2001 Sep; 61(18):6739-46. PubMed ID: 11559545 [TBL] [Abstract][Full Text] [Related]
15. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor. Levenson AS; Tonetti DA; Jordan VC Br J Cancer; 1998 Jun; 77(11):1812-9. PubMed ID: 9667651 [TBL] [Abstract][Full Text] [Related]
16. ICI 182,780, a new antioestrogen with clinical potential. Wakeling AE; Bowler J J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):173-7. PubMed ID: 1525058 [TBL] [Abstract][Full Text] [Related]
17. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Nicholson RI; Gee JM; Manning DL; Wakeling AE; Montano MM; Katzenellenbogen BS Ann N Y Acad Sci; 1995 Jun; 761():148-63. PubMed ID: 7625718 [No Abstract] [Full Text] [Related]
18. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. McClelland RA; Gee JM; Francis AB; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI Eur J Cancer; 1996 Mar; 32A(3):413-6. PubMed ID: 8814683 [TBL] [Abstract][Full Text] [Related]